Highest-materiality recent filing
Cortigent (Vivani subsidiary) to merge into ClearOne (Nasdaq: CLRO) for 12.5M ClearOne shares; Vivani will control combined board.
Received approval from Bellberry HREC in Australia to start SLIM-1 Phase 1 trial of NPM-139 semaglutide implant.
Vivani Medical reports Q1 2026 net loss of $6.8M; SLIM-1 trial on track for mid-2026
Net loss of $6.8M in Q1 2026, up from $6.3M in Q1 2025; R&D expense $4.4M (+4% YoY).
Vivani Medical prices $4.5M common stock offering; Chairman participates in private placement
Gross proceeds of $4.5M from registered direct offering (1.69M shares) and private placement (1.35M shares) at $1.48/share.
Vivani Medical Q3 net loss $6.5M; plans Phase 1 semaglutide implant study in H1 2026
Net loss of $6.5M in Q3 2025 vs $6.0M in Q3 2024; cash down to $4.0M from $19.7M at year-end 2024.
Vivani Medical prices $15.7M equity offering; Chairman participates in $6.0M private placement
Registered direct offering of 6M shares and private placement of 3.7M shares priced at $1.62/share for total gross proceeds of ~$15.7M.
Vivani sets Oct 8 record date for Cortigent spin-off; Cortigent to trade as CRGT
Record date for Cortigent spin-off is October 8, 2025; distribution date and ratio to be announced later.
Vivani Medical plans Phase 1/2 trials for NPM-139 semaglutide implant; H1 2026 start
NPM-139 is a semaglutide implant for chronic weight management in obese/overweight patients.
Vivani Medical raises $10M, reports Q2 loss of $7.1M, advances semaglutide implant NPM-139
Raised $10M via private placement of 7.94M shares at $1.26/share with director-affiliated entity.
Preliminary Q2 2025 cash and cash equivalents $6.8M, plus $11.25M committed capital through March 2026.
Vivani Medical appoints Anthony Baldor as CFO, Brigid Makes resigns
CFO Brigid Makes resigns effective June 15, 2025; no disagreement with company.
Vivani Medical files Form 10 for spin-off of Cortigent; expects Nasdaq listing in Q3 2025
Cortigent files Form 10 to spin off from Vivani as independent Nasdaq company; completion expected Q3 2025.
Vivani Medical Q1 net loss $6.3M; secures $3M private placement; LIBERATE-1 data mid-2025
Q1 net loss of $6.3M (vs $6.0M prior year); cash, equivalents & restricted cash $14.3M as of March 31.
Vivani Medical reports FY2024 net loss $23.5M; obesity implant trials on track for mid-2025 data
FY2024 net loss $23.5M vs $25.7M YoY; cash $19.7M at Dec 31, 2024.
Vivani Medical raises $8.25M in private placement led by Chairman; extends cash runway into Q2 2026
Issued 7,366,071 shares at $1.12 each to an entity beneficially owned by Chairman Gregg Williams.
Vivani Medical Reports Positive Preclinical Data for Once-Yearly Semaglutide Implant NPM-139
NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration in healthy rats over 91 days.
Spin-off of Cortigent into independent public company planned by mid-2025; expects tax-free distribution to Vivani shareholders.
Vivani Medical Q3 net loss $6.0M; $5M equity financing; GLP-1 implant study approved in Australia
Net loss $6.0M for Q3 2024 vs $6.8M YoY; cash $21.0M as of Sept 30, 2024.
Vivani Medical gets Australian approval to start first-in-human GLP-1 implant trial LIBERATE-1
Approval from Bellberry HREC and TGA acknowledgement for LIBERATE-1 trial in obese/overweight subjects.
Vivani Medical reports 82% sham-adjusted liver fat reduction with GLP-1 implant
Sham-implant adjusted liver fat reduction of 82% in obese mouse model from single administration with twice-yearly dosing.
Vivani Medical reports Q2 net loss $5.3M; cash $26.3M; NPM-115 FIH study expected Q4 2024
Cash $26.3M as of June 30, 2024 ($31.0M at March 31, 2024); enough to fund operations into H2 2025.
FDA lifts clinical hold on Vivani Medical's NPM-119, clears IND for Phase 1 trial
FDA cleared IND and lifted clinical hold for NPM-119 (exenatide), a six-month GLP-1 implant for type 2 diabetes.
Vivani Medical Q1 net loss $6.0M, cash $31.0M; NPM-115 IND on track for H2 2024
Net loss of $6.0M in Q1 2024 vs $6.3M in Q1 2023; cash $31.0M at March 31, 2024, up from $22.0M.
Vivani Medical enters into $75M ATM equity offering agreement with Jefferies LLC
Up to $75M of common stock may be sold at-the-market through Jefferies as sales agent.
Vivani Medical shifts focus to GLP-1 obesity implants; Q4 net loss $6.0M
Cash and equivalents $22.0M as of Dec 31, 2023, down from $46.4M; $15M March 2024 financing extends runway into H2 2025.
Vivani Medical appoints Daniel Bradbury to Board; former Amylin CEO led first once-weekly GLP-1 drug
Daniel Bradbury appointed to board effective March 4, 2024, filling newly created vacancy expanding board from 5 to 6 members.
Vivani Medical prices $15M registered direct offering of 3.95M shares and warrants at $3.80
Offers 3,947,368 shares of common stock and warrants to purchase same amount; gross proceeds ~$15.0M.
Vivani reports NPM-115 preclinical weight loss comparable to Ozempic/Wegovy; prioritizes obesity
NPM-115 (exenatide implant) achieved ~20% weight loss in obese mice, similar to semaglutide injections.
Vivani Medical receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified Vivani on Dec 26, 2023 that common stock closed below $1.00 for 30 consecutive trading days through Dec 21, 2023.
Vivani Medical Q3 net loss $6.8M; adds NPM-115 for weight management
Net loss of $6.8M in Q3 2023 vs net income of $1.4M in Q3 2022, driven by prior-year bargain purchase gain.
Vivani Medical provides update on FDA clinical hold for NPM-119 diabetes implant
FDA placed full clinical hold on NPM-119 Phase 2a LIBERATE-1 study on Aug 18, 2023, due to CMC deficiencies.
Vivani's NPM-119 trial on clinical hold; submits Complete Response to FDA
FDA placed LIBERATE-1 study on clinical hold Aug 11, citing insufficient CMC information to assess human subject risks.
Vivani Medical subsidiary Cortigent files for IPO; Vivani to fund ops until offering
Cortigent, Vivani's neuromodulation subsidiary, filed S-1 for IPO; ThinkEquity sole book-runner.
On June 11, 2025, the board of directors (the “Board”) of the Company appointed Anthony Baldor, to serve as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective June 15, 2025.
On June 10, 2025, Brigid Makes notified Vivani Medical, Inc. (the “Company”) of her decision to resign from her role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, of the Company, effective as of June 15, 2025.
unanimously appointed Daniel Bradbury to fill a newly created vacancy on the Board
the Company terminated without cause the employment of Scott Dunbar, a named executive officer in the Company’s 2023 proxy statement and former Acting Chief Executive Officer of the Company’s predecessor, Second Sight Medical Products, Inc., effective as of November 20, 2023
As of the Effective Time, the Board appointed Adam Mendelsohn, as Chief Executive Officer of the Company, Brigid A. Makes, as Chief Financial Officer of the Company, Truc Le, as Chief Operating Officer of the Company, Donald Dwyer, as Chief Business Officer of the Company, and Lisa Porter, as Chief Medical Officer of the Company.
On and as of the Effective Date, the Board appointed Adam Mendelsohn as a director of the Company.
Scott Dunbar, Company’s Acting Chief Executive Officer and Edward Sedo, the Company’s Acting Chief Accounting Officer, resigned as officers of the Company.
As of the Effective Time, the Board appointed Adam Mendelsohn, as Chief Executive Officer of the Company, Brigid A. Makes, as Chief Financial Officer of the Company, Truc Le, as Chief Operating Officer of the Company, Donald Dwyer, as Chief Business Officer of the Company, and Lisa Porter, as Chief Medical Officer of the Company.
Pursuant to the Merger Agreement, immediately prior to and effective upon the Merger, Jonathan Will McGuire and Matthew Pfeffer, resigned from the Board and any respective committees of the Board to which they belonged, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices .
Scott Dunbar, Company’s Acting Chief Executive Officer and Edward Sedo, the Company’s Acting Chief Accounting Officer, resigned as officers of the Company.
As of the Effective Time, the Board appointed Adam Mendelsohn, as Chief Executive Officer of the Company, Brigid A. Makes, as Chief Financial Officer of the Company, Truc Le, as Chief Operating Officer of the Company, Donald Dwyer, as Chief Business Officer of the Company, and Lisa Porter, as Chief Medical Officer of the Company.
As of the Effective Time, the Board appointed Adam Mendelsohn, as Chief Executive Officer of the Company, Brigid A. Makes, as Chief Financial Officer of the Company, Truc Le, as Chief Operating Officer of the Company, Donald Dwyer, as Chief Business Officer of the Company, and Lisa Porter, as Chief Medical Officer of the Company.
Max materiality 0.85 · Median 0.65 · Most common event other_material